References
- Pililis, S.; Lampsas, S.; Kountouri, A.; Pliouta, L.; Korakas, E.; Livadas, S.; Thymis, J.; Peppa, M.; Kalantaridou, S.; Oikonomou, E.; et al. The Cardiometabolic Risk in Women with Polycystic Ovarian Syndrome (PCOS): From Patho-physiology to Diagnosis and Treatment. Medicina 2024, 60, 1656. https://doi.org/10.3390/medicina60101656
- Kim JJ. Obesity and Polycystic Ovary Syndrome. J Obes Metab Syndr. 2024 Dec 30; 33(4): 289–301. doi: 10.7570/jomes24035. Epub 2024 Dec 20. PMID: 39701598; PMCID: PMC11704221.
- Bril F, Ezeh U, Amiri M, Hatoum S, Pace L, Chen YH, Bertrand F, Gower B, Azziz R. Adipose Tissue Dysfunction in Polycystic Ovary Syndrome. J Clin Endocrinol Metab. 2023 Dec 21; 109(1): 10–24. doi: 10.1210/clinem/dgad356. PMID: 37329216; PMCID: PMC10735305.
- Bajuk Studen K, Pfeifer M. Cardiometabolic risk in polycystic ovary syndrome. Endocr Connect. 2018 Jul; 7(7): R238-R251. doi: 10.1530/EC-18-0129. Epub 2018 May 29. PMID: 29844207; PMCID: PMC6026886.
- Amisi CA. Markers of insulin resistance in Polycystic ovary syndrome women: An update. World J Diabetes. 2022 Mar 15; 13(3): 129–149. doi: 10.4239/wjd.v13.i3.129. PMID: 35432749; PMCID: PMC8984569.
- Kim JJ, Choi YM. Dyslipidemia in women with polycystic ovary syndrome. Obstet Gynecol Sci. 2013 May; 56(3): 137–42. doi: 10.5468/ogs.2013.56.3.137. Epub 2013 May 16. PMID: 24327994; PMCID: PMC3784112.
- Milla AMG, Chagas EBF, Miola VFB, Zanuso B, de O, Guiguer EL, Araújo AC, et al. Accuracy of visceral adiposity indices and lipid accumulation products in the identification of adults at high cardiovascular risk. Clínica E Investig En Arterioscler. 2023. https://doi.org/10.1016/j.arteri.2023.04.002
- Wild, Robert A. et al. Lipid levels in polycystic ovary syndrome: systematic review and meta-analysis; Fertility and Sterility, Volume 95, Issue 3, 1073–1079
- Tsouma I, Kouskouni E, Demeridou S, Boutsikou M, et al. Lipid lipoprotein profile alterations in Greek infertile women with polycystic ovaries: influence of adipocytokines levels. In Vivo. 2014 Sep-Oct; 28(5): 935–9.
- Mirdamadi A, Riahinejad S, Varnaseri S. The association between anthropometric parameters and cardiovascular risk indicators in women with polycystic ovarian syndrome. ARYA Atheroscler. 2020 Jan; 16(1): 39–43. doi: 10.22122/arya.v16i1.1804
- Roa Barrios M, Arata-Bellabarba G, Valeri L, Velázquez-Maldonado E. Relationship between the triglyceride/high-density lipoprotein-cholesterol ratio, insulin resistance index and cardiometabolic risk factors in women with polycystic ovary syndrome. Endocrinol Nutr. 2009 Feb; 56(2): 59–65. Spanish. doi: 10.1016/S1575-0922(09)70553-4. Epub 2009 May 1. PMID: 19627713.
- Song do K, Lee H, Sung YA, Oh JY. Triglycerides to High-Density Lipoprotein Cholesterol Ratio Can Predict Impaired Glucose Tolerance in Young Women with Polycystic Ovary Syndrome. Yonsei Med J. 2016 Nov; 57(6): 1404–11. doi: 10.3349/ymj.2016.57.6.1404. PMID: 27593868; PMCID: PMC5011272.
- Soldat-Stankovic V, Popovic Pejicic S, Stan-kovic S, Jovanic J, Bjekic-Macut J, Livadas S, Ognjanovic S, Mastorakos G, Micic D, Macut D. THE EFFECT OF MYOINOSITOL AND METFORMIN ON CARDIOVASCULAR RISK FACTORS IN WOMEN WITH POLYCYSTIC OVARY SYNDROME: A RANDOMIZED CONTROLLED TRIAL. Acta Endocrinol (Buchar). 2021 Apr-Jun; 17(2): 241–247. doi: 10.4183/aeb.2021.241. PMID: 34925574; PMCID: PMC8665246.
- Kazerooni T, Shojaei-Baghini A, Dehbashi S, Asadi N, Ghaffarpasand F, Kazerooni Y. Effects of metformin plus simvastatin on polycystic ovary syndrome: a prospective, randomized, double-blind, placebo-controlled study. Fertil Steril. 2010 Nov; 94(6): 2208–13. doi: 10.1016/j.fertnstert.2009.11.045. Epub 2010 Jan 15. PMID: 20079899.